In final guidance published today healthcare guidance body NICE has recommended the anti-blood clotting drug apixaban (Eliquis, Bristol-Myers Squibb and Pfizer) as an option for treating and preventing venous thromboembolism (VTE) in adults.

VTE is a term used to describe deep vein thrombosis (DVT) and pulmonary embolism (PE). When a blood clot forms in one of the deep veins in the leg, thigh, pelvis or arm it is known as a DVT. If part of the blood clot comes loose it can be carried in the blood to another part of the body where it can cause problems. If the blood clot reaches the lungs (PE) it can be fatal.

DVT can result in long-term illness, including venous ulceration and chronic pain, swelling and skin changes in the affected limb which can have a significant impact on quality of life.

Risk factors for VTE include a history of DVT, recent surgery, immobility, active cancer or cancer treatment, being aged over 60 years, obesity, hormone replacement therapy or oestrogen containing contraceptive therapy and having other conditions such as heart disease.

For more details, go to: http://www.nice.org.uk/news/press-and-media/nice-guidance-recommends-apixaban-eliquis-for-treating-and-preventing-potentially-fatal-blood-clots